|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This systematic review and meta-analysis evaluated the efficacy and safety of induction therapy (12-16 weeks) with biologic therapies targeting the IL-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis.
|
31419343 |
2020 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Risankizumab is a newly FDA-approved IL-23 inhibitor that shows particular promise in the treatment of plaque psoriasis.
|
31672037 |
2020 |
|
Chronic small plaque psoriasis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tildrakizumab (also known as MK-3222), is a high-affinity, humanized, immunoglobin G1κ monoclonal antibody targeting the p19 subunit of interleukin-23 recently approved for the treatment of moderate to severe plaque psoriasis in the US, Europe, and Australia.
|
31536773 |
2019 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hyperactivity of the IL-23/IL-17 axis is central to plaque psoriasis pathogenesis.
|
31129129 |
2019 |
|
Chronic small plaque psoriasis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
|
31583255 |
2019 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis.
|
31354244 |
2019 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate, in a phase II (AMAF; NCT02899988), multicentre, double-blind trial, the efficacy and safety of three doses of mirikizumab (LY3074828), a p19-directed IL-23 antibody, vs. placebo in patients with moderate-to-severe plaque psoriasis.
|
30734266 |
2019 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This meta-analysis evaluated the short-term (12-16 weeks) efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis.
|
29990694 |
2018 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Guselkumab (Tremfya<sup>®</sup>) is a human immunoglobulin G1 λ (IgG1λ) monoclonal antibody (mAb) that blocks the interleukin-23 (IL-23)-mediated signalling pathway and is the first in its class to be approved in adults with moderate to severe plaque psoriasis in several countries, including the USA and EU.
|
30467781 |
2018 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting IL-23p19 with tildrakizumab augments the therapeutic repertoire for patients with moderate-to-severe chronic plaque psoriasis.
|
30081696 |
2018 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The favourable efficacy and safety of guselkumab, an IL-23-specific monoclonal antibody, has been demonstrated in global phase III studies of plaque psoriasis.
|
29222947 |
2018 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-23 inhibitors may offer potential benefits over existing therapies for moderate-to-severe plaque psoriasis in terms of safety, frequency of administration, and efficacy.
|
29478344 |
2018 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease.
|
30249507 |
2018 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review is aimed at collecting preliminary data on IL23p19 blockers developed for the treatment of plaque psoriasis.
|
29103330 |
2018 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To systematically analyze the efficacy and safety of interleukin (IL)-12/23, IL-17, and selective IL-23 inhibitors in moderate to severe plaque psoriasis.
|
29532693 |
2018 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Risankizumab, a fully human IgG monoclonal antibody inhibitor of IL-23, is a therapeutic agent currently in late stage development for use in the treatment of moderate-to-severe plaque psoriasis.
|
30518998 |
2018 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
|
29341192 |
2018 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting IL-23p19 alone may be a promising treatment approach in patients with moderate-to-severe chronic plaque psoriasis, with a downregulation of Th17 and Th22 cell responses, while IL-12 blockade is not required to achieve efficacy in these patients.
|
28271735 |
2017 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23 signaling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with moderate-to-severe plaque psoriasis.
|
28423301 |
2017 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab, a monoclonal antibody that binds to the shared p40 subunit of interleukin (IL)-12 and IL-23, is approved in the USA and Europe for moderate to severe plaque psoriasis.
|
28150333 |
2017 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis.
|
28596043 |
2017 |
|
Chronic small plaque psoriasis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we determined whether there is an association of SNP rs3212227 with the susceptibility of developing plaque psoriasis and with serum levels of IL-12 and IL-23 in Mestizo population in western Mexico.
|
25447399 |
2015 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-23 is associated with plaque psoriasis susceptibility and pathogenesis.
|
25769911 |
2015 |
|
Chronic small plaque psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this randomized, double-blind, placebo-controlled study the safety, tolerability, and clinical response of guselkumab, an anti-IL-23-specific mAb, were evaluated in patients with moderate-to-severe plaque psoriasis.
|
24679469 |
2014 |